Entity

Time filter

Source Type

Cambridge, MA, United States

Grant
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 225.00K | Year: 2014

DESCRIPTION (provided by applicant): New technologies are needed to enable the molecular characterization of the complex relationship between the immune system and cancer. This proposal aims to apply a novel approach to high-dimensional analysis of cancersamples, in order to determine if it can help to elucidate the interactions between the immune system and cancers, and ultimately to correlate these effects with outcome. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: The interaction of theimmune system and cancer is important to outcome but is poorly understood. We are developing a more powerful way to analyze this complex interaction. If successful, this project may enable improvements in the molecular analysis and treatment of cancer.


Grant
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 224.69K | Year: 2014

DESCRIPTION (provided by applicant): There is a need for multiplexed assay technologies that enable diagnostics and detailed characterization of rheumatoid arthritis. In this project we plan to discover new rheumatoid arthritis biomarkers and implement them in a panel of multiplexed assays. We propose a novel approach that offers significant advances over existing methods, including the ability to rapidly develop, validate, and implement highly multiplexed, high- performance assays. If successful, our long-term goal is to transfer these new assays to the clinic as valuable new tools for high sensitivity diagnostics and treatment decision- making. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: We are developing multiplexed assays for rheumatoidarthritis. The assays will be useful for earlier disease detection, classification, and monitoring response to treatment. If successful, this project will improve rheumatoid arthritis diagnosis and aid therapeutic decision-making.


Patent
Prognosys | Date: 2014-03-14

Provided herein are compositions and methods for detecting the binding of a peptide to an MHC molecule, and the binding of a peptide: MHC complex to a TCR. In preferred embodiments, the compositions and methods are in a highly-multiplexed way. The compositions and methods disclosed herein can be used to provide direct information on which peptides are bound to an MHC molecule. Also provided is a method for simultaneously detecting a large number of peptides for binding to an MHC molecule and/or a T cell. A method for detecting competitive binding of a large number of peptides to an MHC molecule and/or a T cell is also disclosed. Also provided herein is a method for simultaneously detecting a large number of specific TCRs. The compositions and methods of the present invention are useful for vaccine design, research and monitoring of autoimmune and infectious disease, immunogenicity testing of therapeutics, and tissue typing.


Grant
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 233.69K | Year: 2012

DESCRIPTION (provided by applicant): The ability to detect rare mutations in a population of sequences is enabling for a wide range of molecular studies that relate shifts in genotype and phenotype to selective pressures. Although recent technologies haveenabled the analysis of entire genomes for common variation, it is still very challenging to detect rare variants in a sample. This proposal aims to develop a new approach to detect rare genetic variants using next- generation sequencing. Our approach hasimplications for the development of diagnostic and theranostic tests, and the development of novel drugs to treat infectious diseases and cancer. PUBLIC HEALTH RELEVANCE: There are over 200 diseases that are caused by mutations in the mitochondrialgenome. Many of these mutations occur at a low frequency and are difficult to detect. By developing a powerful new method to detect rare variants, we aim to address an important unmet medical need.


Patent
Prognosys | Date: 2012-04-09

The present invention provides methods for constructing peptide construct sets and methods of use of these peptide construct sets in assay systems for peptide analysis, and in particular for use in high throughput peptide analysis. The methods allow for analysis of large sets of peptide constructs in a cost-effective manner, employing molecular biological techniques that are both robust and easily parallelized. Thus, the methods allow for the construction of peptide construct sets encompassing, e.g., the human proteome.

Discover hidden collaborations